News Posts List
Can Epigenetics Stop Late-Stage Cancer?
06/24/2015
A new study from the Mayo Clinic hints at a promising treatment for late-stage cancer patients—but a real breakthrough could be years away.
Can you match the ribbon with the correct awareness month?
06/24/2015
The infographic displays the official ribbon colors of various diseases and matches them with awareness months.
Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization
06/24/2015
Interleukin-6 (IL-6) plays a contributory role in the progression and severity of many forms of cancer; it however remains unclear whether the relevance between circulating IL-6 and cancer is causal.
Cancer Awareness Ribbons
06/22/2015
Match the official cancer awareness color with its disease awareness month using this infographic.
Final results from the large sunitinib global expanded-access trial
06/19/2015
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.
Pathways in Renal Cell Carcinoma: An Animated View
06/18/2015
Learn more about a type of kidney cancer called advanced renal cell carcinoma (aRCC) and the pathways involved in the disease in this animated whiteboard...
Improved Survival and Response With Lenvatinib ± Everolimus vs Everolimus Alone in Metastatic RCC
06/17/2015
Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.
Predictive Biomarkers and Nivolumab Activity in mRCC
06/17/2015
This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.
Beating Advanced Cancers: New Epigenomic Block for Advanced Cancer Progression
06/16/2015
Supported by funding from the ASCO Young Investigator Award from the Kidney Cancer Association. A research team led by Mayo Clinic oncologists has found a new way to...
Future perspectives for mTOR inhibitors in renal cell cancer
06/16/2015
Everolimus is a mTOR inhibitor that demonstrates antitumor and antiangiogenic activities.